Halpern, Bruno

Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial

Aronne, L. J., Sattar, N., Horn, D. B., Bays, H. E., Wharton, S., Lin, W.-Y., Ahmad, N. N., Zhang, S., Liao, R., Bunck, M. C., et al. (2024) · JAMA

Pharmacology and Obesity TreatmentBariatric Surgery and Outcomes

Cited by 860

Tirzepatide for Obesity Treatment and Diabetes Prevention

Jastreboff, A. M., le Roux, C. W., Stefanski, A., Aronne, L. J., Halpern, B., Wharton, S., Wilding, J. P. H., Perreault, L., Zhang, S., Battula, R., et al. (2025) · New England Journal of Medicine

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 462

Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial

Wadden, T. A., Chao, A. M., Machineni, S., Kushner, R., Ard, J., Srivastava, G., Halpern, B., Zhang, S., Chen, J., Bunck, M. C., et al. (2023) · Nature Medicine

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 442

Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment

Wharton, S., Aronne, L. J., Stefanski, A., Alfaris, N. F., Ciudin, A., Yokote, K., Halpern, B., Shukla, A. P., Zhou, C., Macpherson, L., et al. (2025) · New England Journal of Medicine

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 189

Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial

Aronne, L. J., Horn, D. B., le Roux, C. W., Chao, A. M., Ho, W., Halpern, B., Griffin, R., Xie, C., Valderas, E. G., Lee, C. J., et al. (2026) · Nature Medicine

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 22